Floatz logo

Sorafenib

Acute Myeloid Leukemia, Adult

The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Acute Myeloid Leukemia, Adult cohort.

Asset / SponsorPhaseRating
Venetoclax
PETHEMA Foundation
Phase 3B
Azacitidine
PETHEMA Foundation
Phase 3B
Fludarabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3B
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 3B
Busulphan
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3B

View all 17 →

Same molecule, other indications

Sorafenib is also rated in:

renal cell carcinomaDormant
BBB
Indicative ·
79 / 100
View asset →
SorafenibDormant
BBB
Indicative ·
75 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →